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Introduction
Dimethylarginine dimethylaminohydrolases (DDAH) metabolise the endogenous nitric oxide
synthase (NOS) inhibitors: asymmetric dimethylarginine (ADMA) and monomethylarginine1.
In sepsis excessive nitric oxide partially contributes to acute circulatory failure;
pharmacological DDAH1 inhibition has been proposed in order to increase circulating
methylarginine concentrations and reduce NO levels2. The NG-methoxyethyl arginine
substituent, SR257, inhibits DDAH1, with an IC50 22 µM, without directly inhibiting
NOSs1,3.
Methods
In vitro DDAH1 assay: Recombinant human DDAH1 activity was measured using
colorometric citrulline assay8 containing ADMA (100 µM), and phosphate buffered saline
(pH7.4); with symmetric dimethylarginine (100 µM), not a substrate for DDAH1, as blank.
Experiments were carried out in duplicate, and repeated on at least 3 separate occasions.
Results
In vitro DDAH1 assay: NG,NG-disubstituted arginine analogues (100 µM) reduced the
activity of human recombinant DDAH1 activity to less than 25% of control in the presence
of 100 µM ADMA substrate. The morpholinyl and pyrrolidinyl substituents reduced hDDAH1
activity to less than 10% of control.
Results
In silico DDAH1 predicted binding: The human DDAH1 (PDB, 2JAJ) structure was used
in silico to generate both Glide docking scores and predicted Autodock4 binding energy for
the known SR257 DDAH1 inhibitor1 and NG,NG-disubstituted arginines (Table 1).
Table 1: Predicted Glide docking score (kcal/mol) and Autodock4 binding energy (kcal/mol) for the
hDDAH1 (PDB 2JAJ).
SR257 (PDB 2JAJ1) forms hydrogen bonds with hDDAH1 Leu29, Asp72, Asp78, Val267,
and Asp268 and hydrophobic interactions with Phe75 and Cys273 (Figure 3). Autodock4
predicted all NG,NG-disubstituted arginines to interact with Asp78, Arg144 and Asp268;
Morpholinyl and Pyrrolidinyl were predicted to interact with Ser31. Methoxyethyl/methyl was
the only NG,NG-disubstituted arginine predicted to interact with Cys273 (Figure 3).
Figure 3: Predicted Human DDAH-1 interactions with NG,NG-disubstituted arginines.
Discussion
Both Autodock4 and Glide docking predicted higher binding energies for morpholinyl,
pyrrolidinyl and piperinyl than the known SR257 compound. The morpholinyl compound
has been described to be a weak inhibitor of hDDAH19. In vitro assays confirmed these
NG,NG-disubstituted arginines reduced DDAH1 activity. There was variation between Glide
and Autodock4 in the docking predictions for methoxyethyl/methyl and N-methylpiperazinyl.
In silico prediction of DDAH1-ligand interactions may assist in the future design and
development of novel NG,NG-disubstituted arginines.










































Chemical synthesis: Acyclic and cyclic NG,NG-
disubstituted arginines were made as previously
described4 using Katritzky’s synthesis preparing
trisubstituted guanidines from di-(benzotriazol-
1-yl)methanimine5.
In silico prediction: Molecular docking was
employed to explore interactions of the NG, NG-
disubstituted arginines (table 1) with human
DDAH1 (PDB 2JAJ; hDDAH1 bound to SR257)
using Glide (Schrödinger6) and Autodock47. The
published SR257 ligand was used to define the
binding site with both software tools.
Figure 1: Human DDAH-1 (PDB 2JAJ)
predicted active site complex with
substrate ADMA.
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SR257 Morpholinyl Pyrrolidinyl
Figure 2: Human DDAH-1 activity, measuring citrulline production; the assay contained ADMA (100 µM) 
with NG,NG-disubstituted arginine analogues (100 µM), n=3, *p<0.05 with ANOVA.
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